The pharmaceutical company Antibiotice S.A. ended last month with a record delivery of products for injection in the US market, a press release informs.
Thus, on Wednesday, June 29, six trucks with injectable anti-infectives with the label ‘made by Antibiotice for the U.S.A’ went to the Port of Constanta.
“Our two anti-infective products, Nafcillin 1 g and 2 g and Ampicillin 500 mg, 1g and 2g will go overseas, to the American patients from hospitals. In addition to these products, the procedure for authorizing in the US market a new Antibiotice product, Ampicillin and sulbactam 1.5 g and 3 g, powder for solution for injection/infusion in two doses was completed,” the release reads.
This is the largest delivery of finished products in the US, a strategic market for Antibiotice, from the beginning of 2016.
With this delivery, the export value of finished products and Nystatin in the American market, in the first semester reached USD 3.4 million, a double value as compared to that achieved in the first half of 2015.
Antibiotice is one of the most important Romanian producers of generic drugs, being present with pharmaceutical products and Nystatin API in Romania and other 72 countries around the world. In terms of Nystatin active ingredient production, Antibiotice ranks first worldwide among the pharmaceutical manufacturers.
In the first three months of 2016 the financial-economic results of the pharma company located in Iasi fall within the forecasted and approved limits. Antibiotice managed to get sales revenues of RON 55.1 million, higher by 5 percent compared with the same period of 2015 and higher by 1 percent compared with the budgeted values. Operating profit (RON 8.1 million) remained at the same level as compared to 2015 and higher by 26 percent compared to the budgeted values.
Internationally, in the first quarter, the company achieved its sales target of USD 5.9 million, higher by 4 percent compared to the same period of the previous year, the biggest shares in exports being recorded in the areas: Europe, Asia, Middle East, North America and Russia.